These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32162602)

  • 1. Regulation of Fas in response to bortezomib and epirubicin in colorectal cancer cells.
    Cacan E; Ozmen ZC
    J Chemother; 2020 Jul; 32(4):193-201. PubMed ID: 32162602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack.
    Cacan E; Spring AM; Kumari A; Greer SF; Garnett-Benson C
    Int J Mol Sci; 2015 Dec; 16(12):30405-21. PubMed ID: 26703577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination treatment of bortezomib and epirubicin increases the expression of TNFRSF10 A/B, and induces TRAIL-mediated cell death in colorectal cancer cells.
    Caldiran F; Berkel C; Yilmaz E; Kucuk B; Cacan AH; Citli S; Canpolat E; Cacan E
    Biochem Biophys Res Commun; 2023 Oct; 675():33-40. PubMed ID: 37451215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progesterone augments epirubicin-induced apoptosis in HA22T/VGH cells by increasing oxidative stress and upregulating Fas/FasL.
    Chang WT; Hsieh BS; Cheng HL; Lee KT; Chang KL
    J Surg Res; 2014 May; 188(2):432-41. PubMed ID: 24594218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy.
    Botti C; Buglioni S; Benevolo M; Giannarelli D; Papaldo P; Cognetti F; Vici P; Di Filippo F; Del Nonno F; Venanzi FM; Natali PG; Mottolese M
    Clin Cancer Res; 2004 Feb; 10(4):1360-5. PubMed ID: 14977837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor.
    Wu T; Chen W; Zhong Y; Hou X; Fang S; Liu CY; Wang G; Yu T; Huang YY; Ouyang X; Li HQ; Cui L; Yang Y
    Mol Cancer Ther; 2017 Apr; 16(4):717-728. PubMed ID: 27903750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells.
    Wang S; Wang L; Zhou Z; Deng Q; Li L; Zhang M; Liu L; Li Y
    Sci Rep; 2017 Apr; 7(1):682. PubMed ID: 28386133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solamargine enhances HER2 expression and increases the susceptibility of human lung cancer H661 and H69 cells to trastuzumab and epirubicin.
    Liang CH; Shiu LY; Chang LC; Sheu HM; Tsai EM; Kuo KW
    Chem Res Toxicol; 2008 Feb; 21(2):393-9. PubMed ID: 18078328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-Myb deficiency boosts bortezomib-induced immunogenic cell death in colorectal cancer.
    Hui YJ; Yu TT; Li LG; Peng XC; Di MJ; Liu H; Gu WL; Li TF; Zhao KL; Wang WX
    Sci Rep; 2024 Apr; 14(1):7733. PubMed ID: 38565963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia Promotes Synergy between Mitomycin C and Bortezomib through a Coordinated Process of Bcl-xL Phosphorylation and Mitochondrial Translocation of p53.
    Song X; Dilly AK; Choudry HA; Bartlett DL; Kwon YT; Lee YJ
    Mol Cancer Res; 2015 Dec; 13(12):1533-43. PubMed ID: 26354682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib-mediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cells.
    Ci X; Li B; Ma X; Kong F; Zheng C; Björkholm M; Jia J; Xu D
    Oncotarget; 2015 Nov; 6(35):38079-92. PubMed ID: 26472030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3.
    Wieder T; Essmann F; Prokop A; Schmelz K; Schulze-Osthoff K; Beyaert R; Dörken B; Daniel PT
    Blood; 2001 Mar; 97(5):1378-87. PubMed ID: 11222383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The essential role of TAp73 in bortezomib-induced apoptosis in p53-deficient colorectal cancer cells.
    Dabiri Y; Kalman S; Gürth CM; Kim JY; Mayer V; Cheng X
    Sci Rep; 2017 Jul; 7(1):5423. PubMed ID: 28710427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Epirubicin and Cisplatin Against 4T1 Breast Cancer Cells are Enhanced by Myrtucommulone-A.
    Izgi K; Iskender B; Sakalar C; Arslanhan A; Yuksek EH; Hizar E; Canatan H
    Anticancer Agents Med Chem; 2017; 17(3):404-414. PubMed ID: 27039926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between Fas/FasL expression and apoptosis of colon adenocarcinoma cell lines.
    Peng ZH; Xing TH; Qiu GQ; Tang HM
    World J Gastroenterol; 2001 Feb; 7(1):88-92. PubMed ID: 11819739
    [No Abstract]   [Full Text] [Related]  

  • 16. Modulation of the mRNA-binding protein HuR as a novel reversal mechanism of epirubicin-triggered multidrug resistance in colorectal cancer cells.
    Lin GL; Ting HJ; Tseng TC; Juang V; Lo YL
    PLoS One; 2017; 12(10):e0185625. PubMed ID: 28968471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
    Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
    Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.
    Wu CL; Ping SY; Yu CP; Yu DS
    Kaohsiung J Med Sci; 2012 Apr; 28(4):194-203. PubMed ID: 22453067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of Both Normal and Tumor Tissues
    Xue Y; Barker N; Hoon S; He P; Thakur T; Abdeen SR; Maruthappan P; Ghadessy FJ; Lane DP
    Cancer Res; 2019 Jul; 79(14):3595-3607. PubMed ID: 31138526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
    Nikrad M; Johnson T; Puthalalath H; Coultas L; Adams J; Kraft AS
    Mol Cancer Ther; 2005 Mar; 4(3):443-9. PubMed ID: 15767553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.